Glomerulonephritis - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glomerulonephritis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Glomerulonephritis - Pipeline Review, H1 2015', provides an overview of the Glomerulonephritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glomerulonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glomerulonephritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Glomerulonephritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Glomerulonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Glomerulonephritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Glomerulonephritis Overview 8
Therapeutics Development 9
Pipeline Products for Glomerulonephritis - Overview 9
Pipeline Products for Glomerulonephritis - Comparative Analysis 10
Glomerulonephritis - Therapeutics under Development by Companies 11
Glomerulonephritis - Therapeutics under Investigation by Universities/Institutes 12
Glomerulonephritis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Glomerulonephritis - Products under Development by Companies 16
Glomerulonephritis - Products under Investigation by Universities/Institutes 17
Glomerulonephritis - Companies Involved in Therapeutics Development 18
Adienne Pharma & Biotech 18
Alexion Pharmaceuticals, Inc. 19
Avexxin AS 20
Biogen Idec Inc. 21
ChemoCentryx, Inc. 22
FibroStatin SL 23
GlaxoSmithKline plc 24
Hansa Medical AB 25
Mallinckrodt plc 26
New Zealand Pharmaceuticals Limited 27
Pharmalink AB 28
Toray Industries, Inc. 29
Glomerulonephritis - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
AVX-235 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
belimumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
budesonide - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CCX-168 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
corticotropin - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DEXM-74 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drug to Inhibit GPBP for Glomerulonephritis and Cancer - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
eculizumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Endoglycosidase of Streptococcus pyogenes - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Mubodina - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Peptide to Inhibit ETA and ETB for Rapidly Progressive Glomerulonephritis - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
rituximab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Glomerulonephritis - Recent Pipeline Updates 62
Glomerulonephritis - Dormant Projects 76
Glomerulonephritis - Discontinued Products 77
Glomerulonephritis - Product Development Milestones 78
Featured News & Press Releases 78
Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon 78
Sep 09, 2011: Adienne Pharma Receives EMA's Positive Opinion For Orphan Drug Designation For Recombinant Human Minibody Mubodina 78
Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon 78
Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon 79
Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon 79
Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon 80
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 81
Disclaimer 82

List of Tables
Number of Products under Development for Glomerulonephritis, H1 2015 9
Number of Products under Development for Glomerulonephritis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Glomerulonephritis - Pipeline by Adienne Pharma & Biotech, H1 2015 18
Glomerulonephritis - Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 19
Glomerulonephritis - Pipeline by Avexxin AS, H1 2015 20
Glomerulonephritis - Pipeline by Biogen Idec Inc., H1 2015 21
Glomerulonephritis - Pipeline by ChemoCentryx, Inc., H1 2015 22
Glomerulonephritis - Pipeline by FibroStatin SL, H1 2015 23
Glomerulonephritis - Pipeline by GlaxoSmithKline plc, H1 2015 24
Glomerulonephritis - Pipeline by Hansa Medical AB, H1 2015 25
Glomerulonephritis - Pipeline by Mallinckrodt plc, H1 2015 26
Glomerulonephritis - Pipeline by New Zealand Pharmaceuticals Limited, H1 2015 27
Glomerulonephritis - Pipeline by Pharmalink AB, H1 2015 28
Glomerulonephritis - Pipeline by Toray Industries, Inc., H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Stage and Target, H1 2015 32
Number of Products by Stage and Mechanism of Action, H1 2015 34
Number of Products by Stage and Route of Administration, H1 2015 36
Number of Products by Stage and Molecule Type, H1 2015 38
Glomerulonephritis Therapeutics - Recent Pipeline Updates, H1 2015 62
Glomerulonephritis - Dormant Projects, H1 2015 76
Glomerulonephritis - Discontinued Products, H1 2015 77